6794 — Unicocell Biomed Co Share Price
0.000.00%
Last trade - 00:00- TWD4.53bn
- TWD4.15bn
- TWD24.59m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.95 | ||
| Price to Tang. Book | 7.96 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 182.76 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.13% | ||
| Return on Equity | -18.71% | ||
| Operating Margin | -391.56% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 15.74 | 3.98 | 8.18 | 14.4 | 24.59 | n/a | n/a | 34.96% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Unicocell Biomed Co Ltd is mainly engaged in the research and development of new adipose stem cell drugs and the application of stem cell technology. The main products include stem cell secretin and cell testing services. The Company's current development projects are divided into human adipose-derived mesenchymal stem cells, autologous adipose stem cell transplantation and cell preparation application products. The clinical trials of human adipose-derived mesenchymal stem cells include the ELIXCYTE-CT21 clinical trial project and the ELIXCYTE-CT31 clinical trial project. Autologous adipose stem cell transplantation is used for large-area burns and difficult wound healing. The cell preparation application products include stem cell secretin, which is a conditioned medium derived from cultured stem cells, used to improve skin dullness and fine lines.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 28th, 2018
- Public Since
- December 25th, 2020
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 55,685,000
- Address
- 6F, No.65, Lane 77, TAIPEI, 114
- Web
- https://www.unicocell.com/
- Phone
- +886 227922699
- Contact
- Yipei Hong
- Auditors
- PricewaterhouseCoopers
Upcoming Events for 6794
Similar to 6794
Abnova Taiwan
Taiwan Stock Exchange
Applied BioCode
Taiwan Stock Exchange
Energenesis Biomedical Co
Taiwan Stock Exchange
Kim Forest Enterprise Co
Taiwan Stock Exchange
PHARMAESSENTIA
Taiwan Stock Exchange
FAQ
What is the Unicocell Biomed Co share price?
As of Today at 11:55 UTC, shares in Unicocell Biomed Co are trading at TWD80.70. This share price information is delayed by 15 minutes.
How has the Unicocell Biomed Co share price performed this year?
Shares in Unicocell Biomed Co last closed at TWD80.70 and the price had moved by -6.05% over the past 365 days. In terms of relative price strength the Unicocell Biomed Co share price has underperformed the FTSE Developed Asia Pacific Index by -10.1% over the past year.
What are the analyst and broker recommendations for Unicocell Biomed Co?
There is no consensus recommendation for this security.
What is the Unicocell Biomed Co dividend yield?
Unicocell Biomed Co does not currently pay a dividend.
Does Unicocell Biomed Co pay a dividend?
Unicocell Biomed Co does not currently pay a dividend.
When does Unicocell Biomed Co next pay dividends?
Unicocell Biomed Co does not currently pay a dividend.
How do I buy Unicocell Biomed Co shares?
To buy shares in Unicocell Biomed Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Unicocell Biomed Co?
As of the previous close price of TWD80.70, shares in Unicocell Biomed Co had a market capitalisation of TWD4.49bn.
Where are Unicocell Biomed Co shares listed?
Here are the trading details for Unicocell Biomed Co:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 6794
What kind of share is Unicocell Biomed Co?
Based on an overall assessment of its quality, value and momentum Unicocell Biomed Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Unicocell Biomed Co share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Unicocell Biomed Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Unicocell Biomed Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -1.86%.
As of the last closing price of TWD80.70, shares in Unicocell Biomed Co were trading -2.66% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Unicocell Biomed Co PE Ratio?
The Unicocell Biomed Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD80.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Unicocell Biomed Co?
We do not have data on Unicocell Biomed Co's directors